ClinicalTrials.gg
RecruitingNCT07478393Updated Oct 20, 2026

Readiness and Progress in Emotion Regulation Therapy

An interventional study of Emotion Regulation Therapy via Telehealth in Rumination, Worry and Self-Criticism, sponsored by Teachers College, Columbia University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Primary conditionDepressionRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depression
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Depression.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Teachers College, Columbia University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Oct 2025, registered Mar 2026).
  • Started Oct 2025; still recruiting 1 year later.
Updated Oct 20, 2026Primary outcomes revisedInterventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,715 studies in Depression with a site in United States — 579 open to participants now, 716 under way, 29 of them phase 3. Depression · United States.

Planned enrollment
2,332nd of 3,322
36 · median 72
Started
2025
with 206 others
No phase
2,221 of 3,715
386 open now
Primary completion
2028-08
later than 547 of 714 live
Registered
3,595th of 3,715
by date

Among the 3,715 studies in Depression with a site in United States, this one is the 2,332nd largest by planned enrollment of the 3,322 interventional ones that give a count, is one of 207 that started in 2025, is one of 2,221 with no phase, reaches primary completion later than 547 of the 714 other live ones, and was the 3,595th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

579 of the 3,715 studies in Depression with a site in United States are open now. Recruiting first, the newest first:

574 more — sign in →

All 579 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,715 studies in Depression with a site in United States, or all of them as a file.
02

Study summary

This study is an open trial designed to examine individual changes that occur before, during, and after 6 modules of Emotion Regulation Therapy (ERT) delivered via telehealth for individuals in New York State who are experiencing elevated worry, rumination, or self-criticism.

Read the detailed description

The main questions this study aims to answer are to:

  1. Examine temporal patterns of ERT-specific treatment mechanisms (attention regulation, metacognitive regulation, motivation regulation, and valued living), relationships between these mechanisms and negative self-referential processing (NSRP; i.e., rumination, worry, and self-criticism) severity over time, and changes in these mechanisms in response to specific intervention strategies/modules.
  2. Investigate the effect of concordance and/or discordance between therapists and clients regarding skill acquisition, treatment goals, and case conceptualizations on treatment mechanisms as well as measures of treatment outcome and satisfaction.
  3. Demonstrate the preliminary efficacy of a 6-module, time-variable version of ERT in reducing symptoms of psychological distress (e.g., anxiety, depression, worry, rumination, self-criticism), changing ERT-specific treatment mechanisms (e.g., attention regulation), and improving quality of life and overall functioning.

Participants will:

  1. Fill out an online pre-screening questionnaire and complete a structured clinical interview via Zoom Healthcare
  2. Be enrolled as a patient at the Dean Hope Center for Educational and Psychological Services (DHCEPS), located at Teachers College
  3. Attend between 12-22 once-weekly telehealth ERT sessions
  4. Complete between 18-28 weekly questionnaires online via Qualtrics (two before starting treatment, 12-22 during each week of treatment, and 4 after ending treatment).
03

Conditions studied

  • Rumination
  • Worry
  • Self-Criticism
  • Anxiety
  • Depression
  • Distress, Emotional

Browse trials for

Keywords

  • Worry
  • Rumination
  • Self-Criticism
  • Emotion Regulation Therapy
  • Emotion Regulation
  • Treatment Mechanisms
04

In context

Depression Reclassified

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

This study's planned enrollment of 36 is below the median of 81 across 7,089 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Teachers College, Columbia University is the lead sponsor of 26 studies on the registry; 8 are open to participants now.

Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between the ages of 18 and 65
  • Fluent in English (and therefore able to provide consent)
  • Currently living in New York State
  • Access to at least one device with internet and video-conferencing capabilities
  • High self-reported worry, rumination, and/or self-criticism
  • Meet - Fifth Edition (DSM-5) criteria for at least one, current psychological disorder

Exclusion criteria

Exclusion Criteria:

  • Active suicidal ideation or intent
  • Substance dependence disorder, schizophrenia, bipolar-I disorder, or a primary diagnosis of borderline or narcissistic personality disorder
  • Currently in therapy or receiving any type of psychosocial treatment
  • Individuals taking psychotropic mediation that has not been stabilized for a period of at least 3 months
  • Current students at Teachers College, Columbia University
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Emotion Regulation Therapy

    All participants will receive a 6-module, time-variable version of Emotion Regulation Therapy delivered weekly via synchronous telehealth using videoconferencing software and an asynchronous Internet-based online platform to supplement the content covered in each session.

    Behavioral: Emotion Regulation Therapy via Telehealth

Interventions

  • BehavioralEmotion Regulation Therapy via Telehealth

    The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).

    Also known as: Emotion Regulation Therapy (ERT)

07

What researchers measure

Primary outcomes

  1. Weekly Assessment of Change in Attentional Control

    The Attentional Control Scale (ACS) is a 20-item measure used to measure difficulties with concentration associated with problems regulating emotions. Items are rated on a 4-point scale from 1 (almost never) to 4 (always), and raw scores range from 20 to 80. Higher scores indicate better attentional control.

    Time frame: Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks)

  2. Weekly Assessment of Change in Decentering

    The decentering subscale of the Experiences Questionnaire (EQ-D) is an 11-item subscale assessing one's ability to distance themselves from their emotional experience. Items are rated on a 5-point scale from 1 (never) to 5 (all the time), and total scores range from 11 to 55. Higher scores indicate better ability to distancing oneself from one's emotional experience.

    Time frame: Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks)

  3. Weekly Assessment of Change in Reappraisal

    The reappraisal subscale of the Emotion Regulation Questionnaire (ERQ-R) is a 6-item measure of the habitual use of cognitive reappraisal to regulate emotions. Items are rated on a 7-point scale from 1 (strongly disagree) to 7 (strongly agree), and total scores range from 6 to 42. Higher scores indicate a better ability to regulate emotions using the strategy of reappraisal.

    Time frame: Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks)

  4. Weekly Assessment of Change in Valued Living/Action

    The Valuing Questionnaire (VQ) is a 10-item measure of the degree to which respondents have lived according to their personal values over the past week. Items are rated on a 7-point scale from 0 (not at all true) to 6 (completely true). The VQ yields two 5-item subscales: Progress, which assesses enactment of values and perseverance toward them, and Obstruction, which assesses disruption of valued living by avoidance of unwanted experiences and distraction from values. Each subscale ranges from 0 to 30. Higher Progress scores indicate more valued living, and higher Obstruction scores indicate greater interference with valued living.

    Time frame: Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)

  5. Weekly Assessment of Change in Clarity of Approach-Avoidance Motivation

    The Mental Representation of Approach Avoidance Questionnaire (MRAAQ) is a 42-item self-report assessment designed to capture the mental representation of approach-avoidance motivation. Respondents rate how true each statement is for them when they are in an emotional moment, on a 5-point scale from 0 (not at all true for me) to 4 (very true for me). Items are summed into six subscales: Anticipation of Threat (8 items; range 0-32), Consummating Safety (7 items; range 0-28), Anticipation of Reward (8 items; range 0-32), Consummating Reward (7 items; range 0-28), Loss (6 items; range 0-24), and Motivational Clarity (6 items; range 0-24). Higher scores on each subscale indicate greater levels of that motivational process. Higher Anticipation of Threat and Loss scores reflect a worse outcome, whereas higher Consummating Safety, Anticipation of Reward, Consummating Reward, and Motivational Clarity scores reflect a better outcome.

    Time frame: Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)

  6. Weekly Assessment of Change in Rumination

    The Rumination-Reflection Questionnaire (RRQ) is a 12-item measure that assesses past-focused rumination with specificity regarding the types of rumination that people may experience. Items are rated on a 5-point scale from 1 (strongly disagree) to 5 (strongly agree), and total scores range from 12 to 60. Higher scores on this measure indicate greater rumination.

    Time frame: Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks)

  7. Weekly Assessment of Change in Worry

    The Penn State Worry Questionnaire - Past Week (PSWQ-PW) is a 15-item adapted version of the original PSWQ that assesses the extent to which worry has been excessive, uncontrollable, and pervasive in the past week. Items are rated on a 7-point scale from 0 (never) to 6 (almost always), and total scores range from 0 to 90. Higher scores on this measure indicate greater worry in the past week.

    Time frame: Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks)

  8. Weekly Assessment of Change in Self-Criticism

    The self-judgment subscale of the Self-Compassion Scale (SCS) contains 5-items and assesses the tendency to self-criticize. Items are rated on a 5-point scale from 1 (almost never) to 5 (almost always), and total scores range from 5 to 25. Higher scores on this measure indicate greater self-criticism.

    Time frame: Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks)

Secondary outcomes

  1. Weekly Assessment of Change in Depression Severity

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Item Bank v. 1.0 - Emotional Distress - Depression - Short Form 8a assess for depression severity. The 8 items are rated on a 5-point scale from 1 (never) to 5 (always), yielding raw scores from 8 to 40. Higher scores on this measure indicate greater depression severity.

    Time frame: Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)

  2. Weekly Assessment of Change in Anxiety Severity

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Item Bank - Emotional Distress - Anxiety - Short Form 8a assess for anxiety severity. The 8 items are rated on a 5-point scale from 1 (never) to 5 (always), yielding raw scores from 8 to 40. Higher scores on this measure indicate greater anxiety severity.

    Time frame: Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)

Other outcomes

  1. Weekly Assessment of Change in Disability/Impairment

    The Sheehan Disability Scale (SDS) is a 3-item scale which assesses impairment in work, social life/leisure activity, family life/home responsibilities, and overall functioning. Each item is rated on an 11-point scale from 0 (not at all) to 10 (extremely), and the three items are summed into a total score ranging from 0 to 30, with higher scores indicating greater functional impairment.

    Time frame: Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)

  2. Weekly Assessment of Change in Life Satisfaction

    The Brief Multidimensional Students' Life Satisfaction Scale (BMSLSS) is a 5-item self-report measure of satisfaction with five life domains: family life, friendships, school experience, oneself, and where one lives. Items are rated on a 7-point scale from 1 (terrible) to 7 (delighted). Total scores range from 5 to 35, with higher scores indicating greater life satisfaction

    Time frame: Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)

  3. Weekly Assessment of Change in Behavioral Regulation

    The Behavioral Dysregulation Scale (BDRS) is a 13-item self-report measure of behavioral emotion dysregulation, or maladaptive behaviors people engage in to modify or manage their emotions. Items are rated on a 5-point scale from 0 (not at all true for me) to 4 (very true for me), and total scores range from 0 to 52, with higher scores indicating greater behavioral dysregulation.

    Time frame: Baseline, Follow-Up (4 Weeks Post-Treatment)

08

Study locations

1 of 1 sites recruiting
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Aug 2028, 33 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 33 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 17, 2026
StartActual
Oct 24, 2025
Primary completionEst.
Aug 1, 2028
CompletionEst.
Sep 1, 2028
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Arm changed Treatment→Emotion Regulation Therapy
Oct 20, 2026
Primary outcomes
2 time frame changed, 8 description edited
What changed in the outcomes
  • Time frameWeekly Assessment of Change in Valued Living/ActionBaseline, 1st Treatment Session, Follow-Up (4 weeks) → Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
  • Time frameWeekly Assessment of Change in Clarity of Approach-Avoidance MotivationBaseline, 1st Treatment Session, Follow-Up (4 weeks) → Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
  • DescriptionWeekly Assessment of Change in Attentional Control: how it is measured was reworded
  • DescriptionWeekly Assessment of Change in Clarity of Approach-Avoidance Motivation: how it is measured was reworded
  • DescriptionWeekly Assessment of Change in Decentering: how it is measured was reworded
  • DescriptionWeekly Assessment of Change in Reappraisal: how it is measured was reworded
  • DescriptionWeekly Assessment of Change in Rumination: how it is measured was reworded
  • DescriptionWeekly Assessment of Change in Self-Criticism: how it is measured was reworded
  • DescriptionWeekly Assessment of Change in Valued Living/Action: how it is measured was reworded
  • DescriptionWeekly Assessment of Change in Worry: how it is measured was reworded
Oct 20, 2026
Secondary outcomes
1 edited, 4 time frame changed, 4 description edited
What changed in the outcomes
  • Time frameWeekly Assessment of Change in Depression SeverityBaseline, 1st Treatment Session, Follow-Up (4 weeks) → Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
  • Time frameWeekly Assessment of Change in Anxiety SeverityBaseline, 1st Treatment Session, Follow-Up (4 weeks) → Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
  • DescriptionWeekly Assessment of Change in Anxiety Severity: how it is measured was reworded
  • DescriptionWeekly Assessment of Change in Depression Severity: how it is measured was reworded
  • Editedother outcomeWeekly Assessment of Change in Behavioral DysregulationRegulationTime frame: Baseline, 1st Treatment Session, Follow-Up (4 weeks) → Baseline, Follow-Up (4 Weeks Post-Treatment)
  • Time frameother outcomeWeekly Assessment of Change in Disability/ImpairmentBaseline, 1st Treatment Session, Follow-Up (4 weeks) → Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
  • Time frameother outcomeWeekly Assessment of Change in Life SatisfactionBaseline, 1st Treatment Session, Follow-Up (4 weeks) → Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
  • Descriptionother outcomeWeekly Assessment of Change in Disability/Impairment: how it is measured was reworded
  • Descriptionother outcomeWeekly Assessment of Change in Life Satisfaction: how it is measured was reworded
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Primary outcomes 2 time frame changed, 8 description edited
    What changed in the outcomes
    • Time frameWeekly Assessment of Change in Valued Living/ActionBaseline, 1st Treatment Session, Follow-Up (4 weeks) → Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
    • Time frameWeekly Assessment of Change in Clarity of Approach-Avoidance MotivationBaseline, 1st Treatment Session, Follow-Up (4 weeks) → Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
    • DescriptionWeekly Assessment of Change in Attentional Control: how it is measured was reworded
    • DescriptionWeekly Assessment of Change in Clarity of Approach-Avoidance Motivation: how it is measured was reworded
    • DescriptionWeekly Assessment of Change in Decentering: how it is measured was reworded
    • DescriptionWeekly Assessment of Change in Reappraisal: how it is measured was reworded
    • DescriptionWeekly Assessment of Change in Rumination: how it is measured was reworded
    • DescriptionWeekly Assessment of Change in Self-Criticism: how it is measured was reworded
    • DescriptionWeekly Assessment of Change in Valued Living/Action: how it is measured was reworded
    • DescriptionWeekly Assessment of Change in Worry: how it is measured was reworded
    Secondary outcomes 1 edited, 4 time frame changed, 4 description edited
    What changed in the outcomes
    • Time frameWeekly Assessment of Change in Depression SeverityBaseline, 1st Treatment Session, Follow-Up (4 weeks) → Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
    • Time frameWeekly Assessment of Change in Anxiety SeverityBaseline, 1st Treatment Session, Follow-Up (4 weeks) → Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
    • DescriptionWeekly Assessment of Change in Anxiety Severity: how it is measured was reworded
    • DescriptionWeekly Assessment of Change in Depression Severity: how it is measured was reworded
    • Editedother outcomeWeekly Assessment of Change in Behavioral DysregulationRegulationTime frame: Baseline, 1st Treatment Session, Follow-Up (4 weeks) → Baseline, Follow-Up (4 Weeks Post-Treatment)
    • Time frameother outcomeWeekly Assessment of Change in Disability/ImpairmentBaseline, 1st Treatment Session, Follow-Up (4 weeks) → Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
    • Time frameother outcomeWeekly Assessment of Change in Life SatisfactionBaseline, 1st Treatment Session, Follow-Up (4 weeks) → Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
    • Descriptionother outcomeWeekly Assessment of Change in Disability/Impairment: how it is measured was reworded
    • Descriptionother outcomeWeekly Assessment of Change in Life Satisfaction: how it is measured was reworded
    Interventions Arm changed Treatment→Emotion Regulation Therapy
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07478393
Lead sponsor
Teachers College, Columbia University
Responsible party
Douglas Mennin (Professor of Clinical Psychology, Director of Clinical Training, Teachers College, Columbia University) — Principal investigator
First posted
Mar 17, 2026
Start date
Oct 24, 2025
Primary completion
Aug 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Oct 20, 2026

Study contacts

Douglas S Mennin
Contact
mennin@tc.columbia.edu
212.678.6609
Moises Hernandez
Contact
emotionregulationtherapy@gmail.com
212.678.6609
Douglas S Mennin
principal investigator · Professor of Clinical Psychology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion